We are live on ! Find out more
XBIO icon

Xenetic Biosciences
XBIO

8 hedge funds and large institutions have $443K invested in Xenetic Biosciences in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding

Funds holding: 6 → 8 (+2)

0.74% less ownership

Funds ownership: 7.38% → 6.64% (-0.74%)

2% less capital invested

Capital invested by funds: $453K → $443K (-$10.3K)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Holders
8
Holders Change
+2
Holders Change %
+33.33%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Capital Management
Vanguard Capital Management
Pennsylvania
+$18.4K
2
SS
SBI Securities
Japan
+$3.09K
3
Morgan Stanley
Morgan Stanley
New York
+$463

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$61.8K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$12.4K
3
TRCT
Tower Research Capital (TRC)
New York
-$340

XBIO Hedge Fund Activity: Q2 2026 in Review

8 of the 8,330 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q2 2026, worth a combined $443K — down 2.3% from $453K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new XBIO positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 3 trimmed.

The largest buyer was Vanguard Capital Management, adding an estimated $18.4K. The largest seller was Renaissance Technologies, cutting an estimated $61.8K.

  • 8 institutional investors held Xenetic Biosciences (XBIO) as of Q2 2026, up from 6 in Q1 2026.
  • Funds reported $443K of Xenetic Biosciences stock for Q2 2026, down 2.3% quarter-over-quarter.
  • 2 funds opened new Xenetic Biosciences positions in Q2 2026 and 0 closed out, a net change of +2 holders.
  • The largest Xenetic Biosciences buyer in Q2 2026 was Vanguard Capital Management, an estimated $18.4K added.
  • The largest Xenetic Biosciences seller in Q2 2026 was Renaissance Technologies, an estimated $61.8K sold.

Based on aggregated 13F filings for Q2 2026.